No products in the cart
N-Acetyl Semax (25mg)
N-Acetyl Semax peptides are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
What is the N-Acetyl Semax peptide?
N-Acetyl Semax is an acetylated form of the Semax peptide. It consists of a 4 amino acid fragment (Met-Glu-His-Phe) from the chain of melanocortin hormones, such as the adrenocorticotropic hormone (ACTH) and a Pro-Gly-Pro fragment. The acetylation of the peptide into N-Acetyl Semax helps reduce the affinity of other ions, such as Cu++, to its N-terminus. This ultimately increases the stability and potency of the peptide.
Molecular Formula: C39H54N10O10S
Molecular Weight: 854.97 g/mol
N-Acetyl Semax Research
N-Acetyl Semax and nootropic usage
N-Acetyl Semax likely has similar or stronger benefits as a nootropic than its unmodified counterpart – Semax. However there are currently only studies investigating the effects of Semax. According to clinical research, Semax can significantly increase memory and attention in healthy but fatigued subjects. Subjects who received the medication had over 70% correct answers on their memory test compared to 41% on average for the control group. Another trial also reports that Semax can significantly increase the activation of various parts of the brain, as observed via functional magnetic resonance imaging (MRI). Lebedeva et al. concluded, “A greater volume of the default mode network rostral (medial frontal cortex) subcomponent was detected in the Semax group in comparison with controls. Resting state fMRI confirmed Semax effects on the neuronal network of the brain and demonstrated topography of these effects.” 
N-Acetyl Semax and neurotropic factors
The neuroprotective effects of Semax stem primarily come from its ability to activate and elevate the levels of neurotrophic factors in the brain, such as Brain-Derived Neurotrophic Factor (BDNF). Clinical research reveals that the ability of Semax to increase the expression of BDNF may have potential in subjects with ischaemic stroke. One study in 110 ischemic stroke subjects who were either at an early or late stage of rehabilitation revealed that therapy with the peptide led to a significant increase in the levels of BDNF. Furthermore, the increase in BDNF correlated with improved recovery after the stroke, especially in subjects at an early stage of rehabilitation. Gusev et al. reported that “there was a positive correlation between BDNF plasma levels and Barthel score, as well as a correlation between early rehabilitation and motor performance improvement.” Another trial also reported that Semax might have neuroprotective effects on the optic nerve in subjects with glaucoma. According to the researchers, Semax demonstrated advantages over traditional neuroprotective treatment for glaucoma.
N-Acetyl Semax and interaction with digestive systems
Semax also appears to possess the properties of an antiulcer agent. According to a 2002 study published in the Bulletin of Experimental Biology and Medicine, Semax is almost 3 times more effective than a placebo in speeding up the healing after a gastric ulcer. 14 days of therapy with Semax led to ulcer healing in almost 90% of subjects receiving intranasal Semax compared to just over 30% in the group receiving placebo. While the effects were remarkable, the scientists did note that further study of Semax in different combinations with standard treatments for peptic ulcers was needed.
- Magrì, A., Tabbì, G., Giuffrida, A., Pappalardo, G., Satriano, C., Naletova, I., Nicoletti, V. G., & Attanasio, F. (2016). Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. Journal of inorganic biochemistry, 164, 59–69. https://doi.org/10.1016/j.jinorgbio.2016.08.013
- Kaplan, A. Y. A., Kochetova, A. G., Nezavibathko, V. N., Rjasina, T. V., & Ashmarin, I. P. (1996). Synthetic acth analogue semax displays nootropic‐like activity in humans. Neuroscience Research Communications, 19(2), 115-123.
- Lebedeva, I. S., Panikratova, Y. R., Sokolov, O. Y., Kupriyanov, D. A., Rumshiskaya, A. D., Kost, N. V., & Myasoedov, N. F. (2018). Effects of Semax on the Default Mode Network of the Brain. Bulletin of experimental biology and medicine, 165(5), 653–656. https://doi.org/10.1007/s10517-018-4234-3
- Gusev, E. I., Martynov, M. Y., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). Éffektivnost’ semaksa pri lechenii bol’nykh na raznykh stadiiakh ishemicheskogo insul’ta [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 118(3. Vyp. 2), 61–68. https://doi.org/10.17116/jnevro20181183261-68
- Kurysheva, N. I., Shpak, A. A., Ioĭleva, E. E., Galanter, L. I., Nagornova, N. D., Shubina, N. I.u, & Shlyshalova, N. N. (2001). “Semaks” v lechenii glaukomatoznoĭ opticheskoĭ neĭropatii u bol’nykh s normalizovannym oftal’motonusom [Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone]. Vestnik oftalmologii, 117(4), 5–8.
- Ivanikov, I. O., Brekhova, M. E., Samonina, G. E., Myasoedov, N. F., & Ashmarin, I. P. (2002). Therapy of peptic ulcer with semax peptide. Bulletin of experimental biology and medicine, 134(1), 73–74. https://doi.org/10.1023/a:1020621124776